Modality
ADC
MOA
C5i
Target
Aβ
Pathway
Lipid Met
Asthma
Development Pipeline
Preclinical
~Feb 2020
→ ~May 2021
Phase 1
~Aug 2021
→ ~Nov 2022
Phase 2
Feb 2023
→ Apr 2030
Phase 2Current
NCT07935732
1,543 pts·Asthma
2023-09→2028-03·Completed
NCT05097440
502 pts·Asthma
2023-02→2030-04·Not yet recruiting
2,045 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-03-091.9y awayPh2 Data· Asthma
2030-04-204.1y awayPh2 Data· Asthma
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Not yet…
P2
Complet…
Catalysts
Ph2 Data
2028-03-09 · 1.9y away
Asthma
Ph2 Data
2030-04-20 · 4.1y away
Asthma
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07935732 | Phase 2 | Asthma | Completed | 1543 | 6MWD |
| NCT05097440 | Phase 2 | Asthma | Not yet recr... | 502 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| NBI-3153 | Neurocrine | Approved | Aβ |